The pharmacological therapy of GH-secreting pituitary tumors is based on somatostatin (SS) analogs that reduce GH secretion and cell proliferation by binding mainly SS receptors type 2 (SST2). Antimigratory effects of SS have been demonstrated in different cell models, but no data on pituitary tumors are available. Aims of our study were to evaluate SST2 effects on migration and invasion of human and rat tumoral somatotrophs, and to elucidate the molecular mechanism involved focusing on the role of cofilin and filamin A (FLNA). Our data revealed that SST2 agonist BIM23120 significantly reduced GH3 cells migration (222% 6 3.6%, p < 0.001) and invasion on collagen IV (231.3% 6 12.2%, p < 0.01), both these effects being reproduced by octreotide and pasireotide. Similar results were obtained in primary cultured cells from human GH-secreting tumors. These inhibitory actions were accompanied by a marked increase in RhoA/ROCK-dependent cofilin phosphorylation (about 2.7-fold in GH3 and 2.1-fold in human primary cells). Accordingly, the anti-invasive effect of the SS analog was mimicked by the overexpression in GH3 cells of the S3D phosphomimetic cofilin mutant, and abolished by both phosphodeficient S3A cofilin and a specific ROCK inhibitor that prevented cofilin phosphorylation. Moreover, FLNA silencing and FLNA dominant-negative mutants FLNA19-20 and FLNA21-24 transfection demonstrated that FLNA plays a scaffold function for SST2-mediated cofilin phosphorylation. Accordingly, cofilin recruitment to agonist-activated SST2 was completely lost in FLNA silenced cells. In conclusion, we demonstrated that SST2 inhibits rat and human tumoral somatotrophs migration and invasion through a molecular mechanism that involves FLNA-dependent cofilin recruitment and phosphorylation.
Introduction
Transsphenoidal surgery is the first-line therapy for GHsecreting pituitary tumors, but surgical outcomes are less favorable for the lesions invading surrounding tissues. 1 Although other subtypes of pituitary tumors, e.g. nonfunctioning tumors, show the greatest tendency to local invasiveness, invasion of the cavernous sinus is a clinical issue also in acromegalic patients, being reported in 20-50% of subjects in different surgical case series. 2, 3 Tumor cell invasion is a complex process of penetration of tissue barriers by cells that involves different steps, including cell adhesion, degradation of the extracellular matrix components and migration. The invasive phenotype of tumor cells is determined by the activity of the cofilin pathway, that tightly regulates the actin cytoskeleton reorganization required for the formation of cell protrusions. Cofilin is an actin severing protein that promotes the polymerization of new actin filaments by both increasing the number of free barbed ends and by providing actin monomers. Cofilin activity is negatively regulated by phosphorylation at Ser3 in the actin binding domain, 4 that is promoted by small GTPases of the Rho family through a cascade of kinases (ROCK, LIMK) and is decreased by different phosphatases. 5 Alterations in the cofilin pathway have been correlated with invasiveness in different tumors, [6] [7] [8] [9] [10] [11] including non-functioning pituitary tumors (NFPTs). 12 Moreover, in NFPTs dopamine (DA) receptor type 2 (DRD2) inhibited cells migration and invasion by increasing cofilin phosphorylation. 12 The main pharmacological target of GH-secreting pituitary tumors is the SS receptor type 2 (SST2), and long acting SS analogs reduce tumor growth and GH secretion in about 2/3 of patients. An inhibitory effect of SS on cell migration and invasion has been demonstrated in pancreatic neuroendocrine tumor cells, 13 prostate carcinoma cells, 14 neuroblastoma cells 15 and endometrial cells 16 while no data on pituitary tumors are available up to date. In addition, an effect of SS on cofilin phosphorylation has never been investigated, although data on neuroendocrine cells suggest a possible crosstalk between SS and cofilin pathway. 13, 17 A role for cell cytoskeleton in pituitary tumors responsiveness to DA and SS analogs has recently been demonstrated. [18] [19] [20] SST2 directly interacts with filamin A (FLNA), 19 ,21 a large actin binding protein able to homodimerize, composed of an N-terminal actin-binding domain and 24 Ig-like repeats of about 96 aminoacids. In tumoral somatotrophs FLNA is essential for SST2-mediated signal transduction and for SST2 expression stability after prolonged agonist stimulation. 19 Among the different partner proteins for which FLNA acts as scaffold, there are components of the cofilin pathway, such as RhoA-and Rho-associated protein kinase ROCK, with a resulting role for FLNA in promoting cofilin phosphorylation. [22] [23] [24] In pancreatic neuroendocrine tumor cells FLNA is required for the inhibition of cell migration mediated by SST2, 13 but the mechanism and the proteins involved have not been investigated. In our work, we first revealed an inhibitory effect of SST2 agonist BIM23120 on rat and human GH-secreting pituitary tumoral cells migration and invasion and we identified the cofilin pathway as a new intracellular signaling pathway activated by SST2 through the FLNA scaffold function.
Material and Methods

Cell cultures
The study was previously approved by the local ethics committee. Informed consent was obtained from all subjects involved in the study. Human pituitary cells were obtained by the transsphenoidal route from 10 patients with GH-secreting tumors not pretreated with SS analogs. Invasion of the cavernous sinus was observed by radiological findings and confirmed during the surgical procedure in 3 cases and this was the only criteria considered to define a tumor as invasive.
Tissues were enzymatically dissociated in DMEM containing 2 mg/mL collagenase at 378C for 2 hr, as previously described. 19 Cells were cultured in DMEM supplemented with 10% FBS, 2 mM glutamine and antibiotics.
Rat tumoral pituitary GH3 cells (ATCC CCL-82.1) were grown in F12K medium supplemented with 15% HS, 2.5% FBS, 2 mM glutamine and antibiotics.
Transwell migration and invasion assays
Transwell assays were performed as previously described. 12 Briefly, 300,000 cells/insert were plated in 24-well inserts with pore diameter of 8 lm (Merck Millipore, Darmstadt, Germany) and incubated for 24 hr at 378C in serum-free medium with the indicated stimuli (BIM23120, octreotide, pasireotide, Y27632). Cells migrated toward the lower chamber, that contained serum (15% HS, 2.5% FBS for GH3 and 10% FBS for GH-secreting tumors) as chemo-attractant, were stained by crystal violet and quantified by reading absorbance at 560 nm. In transwell invasion assays, the upper side of the insert was coated with 0.25 mg/mL of collagen IV (Sigma, St. Louis, MO), the major constituent of basement membrane. 25, 26 A negative control with serum-free medium in lower chamber was used in each experiment.
Apoptosis assay
Caspase-3/7 enzymatic activity was measured using Apo-ONE Homogenous Caspase-3/7 Assay (Promega, Madison, WI) as previously described. 19 Briefly, GH3 cells were incubated with BIM23120 1 lM for 16 hr, 24 hr and 48 hr. Experiments were repeated 3 times and each determination was done in triplicate.
Western blot analysis of cofilin phosphorylation
Cells were incubated for 10 min with or without BIM23120 (10 nM or 1 lm, as indicated). Dihydrochloride ROCK
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inhibitor Y27632 was used at 2.5 lM and cells were pretreated for 30 min. 12 Total proteins were extracted from cultured cells or GH-secreting tumor tissues (n 5 10), quantified by BCA assay, separated on SDS/polyacrylamide gels and transferred to a nitrocellulose filter. P-cofilin (Ser3) or total cofilin antibodies (Cell Signalling, Danvers, MA) were used at 1:1,000. Chemiluminescence was detected using the ChemiDoc-IT Imaging System (UVP, Upland, CA) and analyzed with NIH ImageJ software.
RhoA activation assay
RhoA activation assay was performed according to the manufacturer's instruction (Cytoskeleton, Denver, CO). Briefly, cells were seeded at a density of 4 3 10 6 in a six-well plate with complete medium. The following day the medium was replaced with serum-free medium overnight. Cells were incubated with or without 1 mM BIM23120 for 10 min at 378C. To immunoprecipitate GTP-bound RhoA, 300 lg of total proteins were incubated with 50 lg of a colored glutathionesepharose beads bound GST-fused rhotekin Rho binding domain for 60 min at 48C with gentle rocking. Beads were collected by centrifugation at 13,000 rpm for 1 min at 48C and washed with washing buffer. GTP-bound RhoA was detected by Western blotting assay using a monoclonal antibody against RhoA (1:500). The expression of total RhoA in cell lysates was used to normalize active RhoA against total RhoA.
Plasmids and transfection
Expression vectors coding for wild-type or mutated S3D and S3A cofilin fused to GFP were previously described. 12 FLNA fragments containing repeats 17-18, 19-20 or 21-24 fused to dsRed were described by Peverelli et al. 19 SNAP-tagged SST2 construct was cloned by fusing the N-terminus of SST2 to the SNAP sequence into a pcDNA vector. These vectors were transiently transfected for 48 hr in GH3 cells using Lipofectamine 3000 reagent (Invitrogen, Carlsbad, CA) according to the instruction of the manufacturer. Transfection efficiency was monitored by fluorescence microscopy in each experiment. Only experiments with transfection efficiency >60% were accepted. Corresponding empty vectors were used in each experiment as negative controls.
FLNA silencing
FLNA gene silencing was performed in GH3 cells using rat FLNA smart pool siRNAs and Dharmafect transfection agent 2 (both from Dharmacon, GE Healthcare Life Sciences, Chicago, IL) according to manufacturer's instructions. Preliminary experiments aimed to determine the optimal concentration of siRNAs and the kinetics of silencing of FLNA were performed. 72 hr of silencing was chosen as optimal time point. A negative control siRNA, a non-targeting sequence without significant homology to the sequence of human, mouse or rat transcripts, was used in each experiment. Western blotting was performed in each experiment to control the expression level of FLNA in silenced cells with 1:1,000 dilution of anti-FLNA antibody (Abnova, Taiwan, RC). The membranes were stripped and reprobed with a GAPDH antibody.
Immunofluorescence GH3 cells were cultured over night on 13-mm coverslips coated with polylysine. Cells were transiently transfected for 48 hr with SNAP-tagged SST2 and wild type cofilin-GFP. SST2-SNAP was labeled with Alexa FluorV R 647 for 20 min at 378C. Cells were treated with BIM23120 1 lM for 10 min at 378C. Then cells were fixed, incubated with blocking buffer (5% FBS, 0.3% Triton TM X-100, in PBS) for 1 hr at room temperature and with a FLNA antibody (Abnova, Taiwan, RC) at 1:200, overnight, at 48C. Cells were then incubated with Alexa FluorV R 546-conjugated secondary antibody (ThermoFisher, Rockford, IL), 1:500, for 1 hr at room temperature. Coverslips were mounted on glass slides with ProLong 
Coimmunoprecipitation assay
SST2 immunoprecipitation was performed as previously described. 19 Briefly, 120 lg of total protein were incubated with 2 lg of SST2 (A-8) antibody (Santa Cruz Biotechnology, CA) for 16 hr at 48C and then for 3 hr at 48C with 20 lL of protein A/G Plus-Agarose. Mouse IgG1 isotype control (ThermoFisher, Rockford, IL) was used as a negative control to measure the non-specific binding. Eluted proteins were resolved by SDS-PAGE and transferred to a nitrocellulose filter. To detect cofilin and FLNA in SST2 immunoprecipitates, total cofilin antibody (Cell Signalling, Danvers, MA) and FLNA antibody (Abnova, Taipei City, Taiwan) were used at 1:1,000. The presence of equal amounts of receptor in the immunoprecipitates was confirmed by stripping and reprobing with anti SST2 antibody (UMB-1, Abcam, Cambridge, UK, 1:1,000).
Statistical analysis
The results are expressed as the mean 6 SD a paired twotailed Student's t-test was used to detect the significance between two series of data. p < 0.05 was accepted as statistically significant.
Results
SST2 agonist inhibited migration and invasion of GH3 cells and human primary GH-secreting pituitary tumor cultured cells
We first tested the effects of the SST2-specific agonist BIM23120 (IC50 0.34 nM) on migration and invasion of rat somatomammotroph cells GH3. Transwell assays showed that 24 hr incubation with BIM23120 significantly reduced Molecular Cancer Biology FBS-induced chemotactic migration (222 6 3.6%, p < 0.001) and invasion on collagen IV, the major constituent of basement membrane (231.3 6 12.2%, p < 0.01) (Figs. These data have been replicated in primary cultured cells of human GH-secreting adenomas (222.6 6 13% migration, mean 6 SD of 4 different tumors, p < 0.05, and 233.8 6 24.6% invasion, mean 6 SD of 3 different tumors, p < 0.05, Figs. 1a and 1b) . The basal invasion ability of GH3 cells was comparable to that of primary cultured cells of human GH-secreting tumors (data not shown).
Since BIM23120 exerts proapoptotic effects in GH3 cells, 19 we tested a possible contribution of apoptosis in the reduction of cell migration and invasion by measuring caspase 3/7 activity in time-course experiments. No increase in caspase 3/ 7 activity was measured after 24 hr stimulation with BIM23120 ( Fig. 1c) , excluding a role of apoptosis in the antimigratory effects of SST2. Then we tested the effect of two current available drugs to treat pituitary tumors, octreotide and pasireotide. Both these drugs exerted inhibitory effects on GH3 cells migration (octreotide 225.9 6 4%, p < 0.01, pasireotide 227.6 6 17%, p < 0.05) and invasion on collagen IV (octreotide 222.3 6 6%, p < 0.05, pasireotide 228.4 6 19%, p < 0.05).
SST2 increased cofilin phosphorylation through activation of RhoA and ROCK
To investigate the intracellular signaling pathway involved in the anti-migratory and anti-invasive actions of SST2, we tested the effects of BIM23120 on the phosphorylation status of cofilin.
Western blot analysis demonstrated that 10 min incubation with BIM23120 significantly increased phosphorylated cofilin (P-cofilin)/total cofilin ratio in both GH3 cells (2.7-fold over basal at 1 lM, p < 0.05, Fig. 2a ) and primary cultures from human GH-secreting tumors (2.1-fold over basal at 10 nM, p < 0.05, Fig. 2b) .
We then tested the involvement of Rho-associated protein kinase ROCK in mediating the effects of SST2 on cofilin phosphorylation. As shown in Figure 2c , ROCK inhibitor Y27632 completely reversed the ability of SST2 to increase cofilin phosphorylation in GH3 cells. Incubation with Y27632 alone slightly but significantly decreased basal P-cofilin/total cofilin ratio, suggesting the presence of a basal activity of ROCK.
To further investigate the mechanism by which SST2 activates ROCK, we measured the ability of BIM23120 to activate RhoA that in the GTP-bound active state binds its downstream effector ROCK. We found that 10 min incubation with 1 lM BIM23120 induced a 2.7-fold over basal increase in GTP-bound Rho-A in GH3 cells (Fig. 2d) .
Cofilin phosphorylation increase was necessary and sufficient for the inhibition of cell invasion
To test the causal role of cofilin phosphorylation in BIM23120-induced inhibition of cell invasion, we coincubated cells with BIM23120 and ROCK inhibitor Y27632.
Y27632 incubation completely abolished the anti-invasive effect of BIM23120 in GH3 cells (Fig. 2e) and the same results were obtained also in 2 human GH-secreting tumors, suggesting that ROCK-dependent cofilin phosphorylation is essential for the inhibition of cell invasion mediated by SST2.
To test whether an increase in cofilin phosphorylation can reproduce the inhibitory effects of BIM23120 on cell migration and invasion, we transfected GH3 cells with a cofilin mutant in which serine 3 is substituted with an aspartate that mimics a phosphoserine (S3D). Transwell assays showed that S3D cofilin transfection significantly inhibited GH3 cells invasion with respect to empty vector (224.2 6 4%, p < 0.001). This effect is specific for the phosphomimetic cofilin, since both wild type cofilin and S3A cofilin that cannot be phosphorylated, showed no effect on cell invasion (Fig. 2f) . Moreover, S3A but not wild type cofilin overexpression reverted the ability of BIM23120 to inhibit cell invasion (Fig. 2f) .
To test an association between GH-secreting tumors invasiveness and cofilin phosphorylation status, we performed Western blot analysis. We found a tendency to higher P-cofilin/total cofilin ratio in non-invasive with respect to invasive tumors (mean P-cofilin/total cofilin ratio was 1.1 and 0.56, respectively, p > 0.05; data not shown) but the sample size (3 invasive and 7 non-invasive tumors) was too small to draw conclusions.
FLNA silencing abolished the ability of SST2 to both increase cofilin phosphorylation and reduce cell invasion
We tested the ability of BIM23120 to increase cofilin phosphorylation in the absence of FLNA by transiently transfecting GH3 cells with specific siRNAs for FLNA or negative control siRNAs. Western blot analysis showed that FLNA silencing completely abolished the cofilin phosphorylation increase observed after BIM23120 incubation in cells transfected with negative control siRNAs (Fig. 3a) . Moreover, no reduction of cell invasion was measured after BIM23120 incubation in cells silenced for FLNA (Fig. 3b) .
FLNA scaffold function was required for SST2-mediated cofilin phosphorylation increase
To dissect the mechanism by which FLNA mediates SST2 actions, we used two FLNA dominant-negative mutants, FLNA19-20 and FLNA21-24 that allow selective uncoupling of SST2 from endogenous FLNA or from signaling molecules binding FLNA scaffold region, respectively. 19 As expected, BIM23120 incubation induced an increase in P-cofilin/total cofilin ratio in control cells transfected with empty vector or control peptide FLNA17-18, but this effect was totally abrogated in cells transfected with both FLNA19-20 and FLNA21-24 (Fig. 3c) , confirming the necessity of SST2-FLNA interaction and also demonstrating the requirement of scaffold function of FLNA for SST2-induced cofilin phosphorylation.
Molecular Cancer Biology Peverelli et al.
We then tested the effects of BIM23120 on cell invasion in cells expressing truncated FLNA mutants. Surprisingly, both FLNA19-20 and FLNA21-24 exerted inhibitory effects on basal cell invasion, that were unaffected by the presence of BIM23120 (Fig. 3d) , suggesting that these FLNA domains are able to interfere with intracellular mechanisms of migration and invasion. The graphs show the quantification of P-cofilin/tot cofilin ratio normalized vs. respective basal (mean 6 SD from 3 independent experiments on GH3 or mean 6 SD from independent experiments on 5 tumors). Representative immunoblots were shown. (c) SST2-mediated cofilin phosphorylation required activation of ROCK. GH3 cells were incubated with 1 lM BIM23120 and/or Y27632 and western blot analysis was performed. The graph shows the quantification of P-cofilin normalized to tot cofilin (mean value 6 SD from 3 independent experiments). (d) RhoA activation assay. GH3 cells were incubated with or without 1 mM BIM23120 for 10 min. GTP-bound RhoA was immunoprecipitated by rhotekin Rho binding domain beads and detected by Western blotting using a RhoA-specific antibody. Cell lysates loaded with GTPgS or GDP have been included as positive (Ctrl 1) or negative (Ctrl 2) controls, respectively. The expression of RhoA in cell lysates of each sample was used to normalize active RhoA against total RhoA. The picture is representative of 3 independent experiments. (e) Y27632 reversed the ability of SST2 to inhibit GH3 cell invasion. GH3 cells were incubated for 24 hr with BIM23120 and/or Y27632 in the upper chamber of a transwell insert coated with collagen IV. The graph represents mean value 6 SD from 3 independent experiments. (f) S3D cofilin overexpression inhibited basal GH3 cell invasion and S3A cofilin overexpression abolished the anti-invasive effects of BIM23120. GH3 cells were transiently transfected for 48 hr with the indicated constructs and incubated with or without BIM23120 1 lM for 24 hr prior to perform transwell assay. Mean values 6 SD from 3 independent experiments are shown.
FLNA was required for cofilin recruitment to activated SST2
To further investigate FLNA role in mediating cofilin pathway activation by SST2, we tested interaction among FLNA, SST2 and cofilin.
Immunofluorescence experiments in GH3 cells exhibited a colocalization among SST2, FLNA and cofilin after 10 min BIM23120 stimulation (Fig. 4a) .
Moreover, we performed immunoprecipitation assays of SST2 in GH3 cells incubated for 10 min with or without BIM23120. Immunoblots showed that SST2 is able to coimmunoprecipitate both FLNA and cofilin in basal conditions, and that agonist stimulation increased FLNA and cofilin recruitment. The same results were obtained in negative control siRNAs transfected cells (Fig. 4b) . However, in FLNA silenced cells cofilin was nearly undetectable in SST2 immunoprecipitates, both in basal condition and upon agonist challenge (Fig. 4b) , suggesting that FLNA is required for cofilin recruitment to SST2.
Discussion
In this work, we first demonstrated that SST2 mediates inhibitory signals for cell migration and invasion in rat and human GH-secreting pituitary tumor cells, with a molecular mechanism involving FLNA-mediated cofilin phosphorylation.
The basal invasive ability of human GH-secreting tumors was identical to that of GH3 cells, but lower than that of NFPT cells. 12 Indeed, although we cannot directly compare the results obtained with GH-secreting tumor cells, growing in adhesion and detected by crystal violet staining, with those obtained with NFPT cells, growing in suspension and detected by Calcein AM staining, 12 we observed that the incubation time required to detect basal cell invasion was much higher for GH-secreting tumors (24 hr) than for NFPT (6 hr). 12 The reduced invasiveness observed in vitro is in agreement with the clinical tumor behavior of GH-secreting tumors, generally less invasive than NFPTs.
The anti-migratory and anti-invasive effects of BIM23120 were comparable in GH3 cells and primary human pituitary tumor cells. Furthermore, similar inhibitory effects were exerted in GH3 cells by the two clinically available somatostatin analogs: octreotide, with high preferential binding affinity for SST2, and pasireotide, with a broader spectrum of affinity for different receptor subtypes and a 40-100 times higher binding affinity to SST5. Since octreotide, pasireotide and BIM23120 induced a similar inhibition of migration and invasion of GH3 cells, that endogenously express both SST2 and SST5, we can hypothesize that these effects are mainly mediated by the activation of SST2.
The analysis of the pathway involved in the regulation of cell motility revealed that BIM23120 induced an increase in P-cofilin/total cofilin ratio, that was mediated by ROCK and was required for the anti-invasive effects of SST2. Indeed, ROCK inhibitor Y27632 completely abolished BIM23120 effects on both cofilin phosphorylation and cell invasion. The involvement of RhoA/ROCK/LIMK/cofilin pathway was further supported by the demonstration that BIM23120 treatment strongly activated RhoA in GH3 cells.
Furthermore, we showed that an increase in phosphorylated cofilin was able to reduce GH3 cell invasion independently from SST2 activation. Indeed, transfection of phosphomimetic cofilin mutant S3D reproduced the inhibitory effect on cell invasion of BIM23120, whereas no effect was observed after transfection of phosphodeficient S3A or wild type cofilin. These results indicate that in GH3 cells S3D cofilin functions in a dominant-negative manner, in agreement with previous observations in other cell lines suggesting that phosphomimetic cofilin competes with endogenous phosphorylated cofilin for binding to specific phosphatases, thus increasing the pool of phosphorylated cofilin. [27] [28] [29] The absence of S3A cofilin effects on basal cell invasion might suggest that cofilin dephosphorylation is not sufficient to initiate cell migration and other mechanisms might be required for the initial activation of cofilin, as described in mammary tumor cells. 30, 31 As expected, this non-phosphorylatable cofilin mutant completely abolished the anti-invasive effect of BIM23120, further demonstrating that cofilin phosphorylation is required to mediate the inhibitory action of SST2. [19] [20] and scaffold region (repeats 21-24) are shown. FLNA functions as scaffold that tether Rho small GTPase and cofilin upstream kinases (ROCK, LIMK) in close proximity, promoting the efficiency of cofilin phosphorylation. P-cofilin is not able to bind actin and thus represent the inactive form of this protein. In this scenario, FLNA by its ability to bind both SST2 and actin fibers, allows SST2-mediated fine-tuning of the spatiotemporal dynamics of the cofilin phosphorylation. The consequent reduction of cofilin activity prevents the formation of protrusive structures and ultimately stops cell migration.
Since FLNA is able to function as scaffold protein for components of the cofilin pathway, [22] [23] [24] to better define the mechanism by which SST2 activates the cofilin pathway, we focused on FLNA role. We used two different approaches: (1) FLNA genetic silencing; (2) transfection of FLNA dominant-negative mutants specific for FLNA binding to SST2 or to signaling molecules.
Silencing experiments in GH3 cells exhibited that in the absence of FLNA, BIM23120 lost its ability to both increase cofilin phosphorylation and decrease cell invasion, demonstrating a crucial role for FLNA in mediating SST2 antiinvasive signaling.
As an alternative approach, we used previously described FLNA dominant-negative mutants. 19 FLNA repeats 19-20 contain the SST2-binding domain, 21 thus FLNA19-20 competes with endogenous FLNA for SST2 binding, but does not contain the actin binding domain and the FLNA scaffold domains. Consequently, its overexpression in GH3 cells results in the loss of both SST2 anchoring to actin cytoskeleton and formation of SST2-FLNA-transducing molecules complexes. 19 Since FLNA repeats 21-24 are mainly involved in scaffolding function for many partner proteins, the overexpression of FLNA21-24 selectively abolishes the ability of FLNA to function as scaffold but does not affect the ability of SST2 to bind endogenous FLNA. To exclude non-specific effects, we used as a control a FLNA fragment containing repeats 17-18 that do not interact with SST2 nor actin cytoskeleton and, based on published data, are not involved in the scaffolding functions of FLNA. Our results showed that both FLNA19-20 and FLNA21-24 completely abolished BIM23120 action on cofilin phosphorylation. These data not only confirm that uncoupling SST2 from FLNA abolishes the ability of BIM23120 to increase cofilin phosphorylation, but also suggest that FLNA21-24 competes with endogenous FLNA for binding to molecules belonging to cofilin pathway, abolishing the scaffold function of FLNA in mediating SST2 signal transduction.
We could not verify if FLNA dominant-negative mutants also abolished the anti-invasive properties of SST2, because the overexpression of FLNA19-20 and 21-24 in the absence of BIM23120 stimulation resulted in a significant reduction of GH3 cell invasion. These data first revealed a role of these peptides as inhibitors of cell invasion. The molecular mechanisms involved are probably related to the ability of FLNA to bind different key mediators of cell adhesion and migration. In particular, FLNA repeats 19-21 are required for cell spreading and initiation of cell migration. 32 Moreover, both FLNA dominant-negative mutants are involved in the binding with the integrin b cytoplasmic tail, competing with talin, a major integrin activator. 33, 34 Confocal microscopy showed that SST2 colocalized with FLNA and cofilin at the plasma membrane after agonist activation. To test the hypothesis that FLNA acts as scaffold mediating SST2 interaction with cofilin, we searched for the presence of FLNA and cofilin in the SST2 immunoprecipitates in GH3 cells stimulated or not with BIM23120. We found that SST2 in basal condition interacted with cofilin and FLNA, and that agonist stimulation increased SST2 interaction with both proteins. The ability of SST2 to coimmunoprecipitate cofilin was completely lost in cells silenced for FLNA, suggesting that agonist-activated SST2 recruits a protein complex that through FLNA scaffold region links cofilin and probably upstream kinases, thus leading to cofilin phosphorylation. Since FLNA bind both SST2 and actin fibers, it is tempting to speculate that FLNA, in addition to anchor SST2 to cytoskeleton, allows the assembly of a macromolecular complex through which SST2 regulates the remodeling of the actin cytoskeleton itself, with possible effects on a variety of cellular processes including cell motility, internalization, trafficking and secretion (Fig. 5) .
Admittedly, a limitation of our study is the use of only one cell line as well as the small number of samples of GHsecreting tumors analyzed. Further studies are needed to confirm and strengthen these results in human cells.
In conclusion, these data reveal new signaling pathways activated by SST2, first documenting an inhibitory effect on GH-secreting tumor cells invasion and migration, and a new role for SST2 in orchestrating the recruitment of a protein complex able to regulate actin cytoskeleton dynamics.
